Johnson & Johnson Temporarily Pulls New Treatment for Atrial Fibrillation to Probe Adverse Events
In This Article:
Johnson & Johnson (JNJ) Wednesday said it paused the rollout of Varipulse cardiac device in the US e
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.